Results (
English) 2:
[Copy]Copied!
Particularly in 2016, the company set a sales target of 2,100 billion.
At the annual general meeting of shareholders of JSC Traphaco 2016 (code: TRA), Ms. Vu Thi Thuan - Chairman of the company summed up the results of activity in 5 years old tenure. Accordingly, in the past 5 years, TRA revenue growth, the average profit was 18.1% and 22.1% - the highest growth rate in the number of businesses listed Pharmacology.
2015, companies reached 1,974 billion in sales - up 20% and 180 billion profit after tax - increased 23.3% compared to 2014. the market share of 1% Traphaco total pharmaceutical market in Vietnam and is located in the top20 company revenue Pharmaceuticals market leader.
the breakthrough of the last term is the sales policy changes. The company has focused on the OTC market, moving from wholesale to retail, and thus regain strong growth for Traphaco.
The tenure from 2016 - 2020, Traphaco planned revenue growth of at least 12% / year, profit growth of 15% / year. Notably, the charter capital is expected to increase to 2 times by bonus shares, in 3 tranches. Dividends 30% / year / charter capital (including the increase of charter capital) and was paid in cash.
Particularly in 2016, the company set a sales target of 2,100 billion. In particular, the production and distribution of goods exclusive of 1,500 billion, imports trusts and retail operators is 260 billion, consolidated revenue from subsidiaries 340 billion. Planning tax profit of the parent company shareholders was 210 billion.
The ratio of dividend expected 30% in 2016.
Being translated, please wait..